Literature DB >> 34506322

Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis.

Dijoia B Darden1, Scott C Brakenridge1, Philip A Efron1, Gabriela L Ghita2, Brittany P Fenner1, Lauren S Kelly1, Alicia M Mohr1, Lyle L Moldawer1, Frederick A Moore1.   

Abstract

OBJECTIVE: To analyze serial biomarkers of the persistent inflammation, immunosuppression, and catabolism syndrome (PICS) to gain insight into the pathobiology of chronic critical illness (CCI) after surgical sepsis.
BACKGROUND: Although early deaths after surgical intensive care unit sepsis have decreased and most survivors rapidly recover (RAP), one third develop the adverse clinical trajectory of CCI. However, the underlying pathobiology of its dismal long-term outcomes remains unclear.
METHODS: PICS biomarkers over 14 days from 124 CCI and 225 RAP sepsis survivors were analyzed to determine associations and prediction models for (1) CCI (≥14 intensive care unit days with organ dysfunction) and (2) dismal 1-year outcomes (Zubrod 4/5 performance scores). Clinical prediction models were created using PIRO variables (predisposition, insult, response, and organ dysfunction). Biomarkers were then added to determine if they strengthened predictions.
RESULTS: CCI (vs RAP) and Zubrod 4/5 (vs Zubrod 0-3) cohorts had greater elevations in biomarkers of inflammation (interleukin [IL]-6, IL-8, interferon gamma-induced protein [IP-10], monocyte chemoattractant protein 1), immunosuppression (IL-10, soluble programmed death ligand-1), stress metabolism (C-reactive protein, glucagon-like peptide 1), and angiogenesis (angiopoietin-2, vascular endothelial growth factor, vascular endothelial growth factor receptor-1, stromal cell-derived factor) at most time-points. Clinical models predicted CCI on day 4 (area under the receiver operating characteristics curve [AUC] = 0.89) and 1 year Zubrod 4/5 on day 7 (AUC = 0.80). IL-10 and IP-10 on day 4 minimally improved prediction of CCI (AUC = 0.90). However, IL-10, IL-6, IL-8, monocyte chemoattractant protein 1, IP-10, angiopoietin-2, glucagon-like peptide 1, soluble programmed death ligand-1, and stromal cell-derived factor on day 7 considerably improved the prediction of Zubrod 4/5 status (AUC = 0.88).
CONCLUSIONS: Persistent elevations of PICS biomarkers in the CCI and Zubrod 4/5 cohorts and their improved prediction of Zubrod 4/5 validate that PICS plays a role in CCI pathobiology.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34506322      PMCID: PMC8592255          DOI: 10.1097/SLA.0000000000005067

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  45 in total

1.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

2.  Why have clinical trials in sepsis failed?

Authors:  John C Marshall
Journal:  Trends Mol Med       Date:  2014-02-24       Impact factor: 11.951

3.  The epidemiology of sepsis in general surgery patients.

Authors:  Laura J Moore; Bruce A McKinley; Krista L Turner; S Rob Todd; Joseph F Sucher; Alicia Valdivia; R Matthew Sailors; Lillian S Kao; Frederick A Moore
Journal:  J Trauma       Date:  2011-03

Review 4.  Enhancing Recovery From Sepsis: A Review.

Authors:  Hallie C Prescott; Derek C Angus
Journal:  JAMA       Date:  2018-01-02       Impact factor: 56.272

5.  Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014.

Authors:  Chanu Rhee; Raymund Dantes; Lauren Epstein; David J Murphy; Christopher W Seymour; Theodore J Iwashyna; Sameer S Kadri; Derek C Angus; Robert L Danner; Anthony E Fiore; John A Jernigan; Greg S Martin; Edward Septimus; David K Warren; Anita Karcz; Christina Chan; John T Menchaca; Rui Wang; Susan Gruber; Michael Klompas
Journal:  JAMA       Date:  2017-10-03       Impact factor: 56.272

6.  Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis.

Authors:  Julie A Stortz; Tyler J Murphy; Steven L Raymond; Juan C Mira; Ricardo Ungaro; Marvin L Dirain; Dina C Nacionales; Tyler J Loftus; Zhongkai Wang; Tezcan Ozrazgat-Baslanti; Gabriela L Ghita; Babette A Brumback; Alicia M Mohr; Azra Bihorac; Philip A Efron; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge
Journal:  Shock       Date:  2018-03       Impact factor: 3.454

7.  The Glue Grant experience: characterizing the post injury genomic response.

Authors:  A G Cuenca; R V Maier; J Cuschieri; E E Moore; L L Moldawer; R G Tompkins
Journal:  Eur J Trauma Emerg Surg       Date:  2011-09-02       Impact factor: 3.693

8.  Burn Injury May Have Age-Dependent Effects on Strength and Aerobic Exercise Capacity in Males.

Authors:  Eric Rivas; Kevin Sanchez; Janos Cambiaso-Daniel; Ileana L Gutierrez; Joan Tran; David N Herndon; Oscar E Suman
Journal:  J Burn Care Res       Date:  2018-08-17       Impact factor: 1.845

Review 9.  Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy.

Authors:  Hiroyuki Horiguchi; Tyler J Loftus; Russell B Hawkins; Steven L Raymond; Julie A Stortz; McKenzie K Hollen; Brett P Weiss; Elizabeth S Miller; Azra Bihorac; Shawn D Larson; Alicia M Mohr; Scott C Brakenridge; Hironori Tsujimoto; Hideki Ueno; Frederick A Moore; Lyle L Moldawer; Philip A Efron
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

10.  Phenotypic heterogeneity by site of infection in surgical sepsis: a prospective longitudinal study.

Authors:  Julie A Stortz; Michael C Cox; Russell B Hawkins; Gabriela L Ghita; Babette A Brumback; Alicia M Mohr; Lyle L Moldawer; Philip A Efron; Scott C Brakenridge; Frederick A Moore
Journal:  Crit Care       Date:  2020-05-07       Impact factor: 9.097

View more
  1 in total

1.  Incidence and outcomes of secondary infections in septic patients with cancer.

Authors:  Shi-Ning Qu; Hai-Jun Wang; Chu-Lin Huang; Hao Zhang; Hao Wang; Zhen-Nan Yuan; Xue-Zhong Xing
Journal:  World J Emerg Med       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.